Back

Economic evaluation of sacubitril/valsartan for the treatment of heart failure with reduced ejection fraction

29 August 2016 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 4 - The wide world of cardiovascular research and practice Psycho-social, economic, cultural, occupational diseases ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Panagiotis STAFYLAS

HealThink, Thessaloniki (Greece)

20 More presentations in this session

Presentation thumbnail
Mr J. Gallagher (Dublin 9, IE)
Abstract
Presentation thumbnail
Doctor J. Cameron (Melbourne, AU)
Abstract Slides
Presentation thumbnail
Doctor X. Li (Chengdu, CN)
Abstract Slides
Presentation thumbnail
Doctor R. Reibis (Potsdam, DE)
Abstract Slides
Presentation thumbnail
Doctor E. Kunschitz (Vienna, AT)
Abstract Slides

Access the full session

Session thumbnail
Poster session 4 - The wide world of cardiovascular research and practice

The Event

Event poster

ESC Congress 2016

29 August 2016 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Cost-effectiveness of Sacubitril/Valsartan in acute and chronic heart failure with reduced ejection fraction: from randomized controlled trials to real-world evidence
22 May 2023
thumbnail
Congress Session
Pioneering advances in HFrEF management: unlocking the potential of sGC stimulation
18 May 2025
thumbnail
Congress Presentation
Cardiorenal trade-off of sacubitril/valsartan in heart failure with reduced ejection fraction and advanced chronic kidney disease: a propensity-weighted multicentre analysis
31 August 2026
thumbnail
Congress Presentation
Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources